Sheridan Ross Co-President Gary Connell was quoted in a Feb. 16 article in BioWorld Today regarding a recent U.S. Patent and Trademark Office case for Johnson & Johnson, which received a final rejection on its patent related to Remicade, a drug used to treat Crohn’s disease, colitis and other autoimmune disorders. The ruling provided some indication that patent law related to novel biologics is rapidly changing and the makers of biosimilar or generic drugs may benefit.
Mr. Connell was quoted about what Johnson & Johnson’s options are now that it has received a final rejection, and he also shared his thoughts on what prospects biosimilar companies may have under this ruling. Read more here.